Search

Your selection

Clear all

Filter by content type

Filter by content year

News

Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

December 2, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 19, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results

November 13, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … regarding clinical results and trial data, including their design, and the timing of such trials and of receiving and … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
News

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

November 7, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024

October 24, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

October 15, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

September 30, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 30, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

August 28, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s …
News

Vaxart Provides Business Update and Reports Second Quarter 2024 Financial Results

August 8, 2024 - … oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s … regarding clinical results and trial data, including their design, and the timing of such trials and of receiving and … whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by …
Scroll to Top